Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock share price logo

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

NASDAQ: FBIOP

$18.24

+0.02

(+0.11%)

as on

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Stock Performance

as on August 20, 2026 at 6:58 am IST

  • Day's Low

    Day's High

    $18.05
    $18.33
    downward going graph

    1.04%

    Downside

    0.49%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock share price movements today

Previous Close
$18.22
Open
$18.32
Volume
191.5K
Market Cap
$77.8M
Day's Low - High
$18.05 - $18.33

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Historical Returns

1 Month Return
-0.29 %
3 Month Return
+ 24.28 %
1 Year Return
+ 136.74 %
3 Year Return
+ 133.77 %
5 Year Return
-26.38 %

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Stock Fundamentals & Key Indicators

Check Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$77.8M

EPS (TTM)

0

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

115.99%

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock image
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
BUY$77.8M-26.38%NA163.32%NA
Revolution Medicines image
Revolution Medicines
BUY$43.7B669.3%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$128.2B154.86%29.8286.04%NA
Regeneron image
Regeneron
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Stock including INR - Dollar returns

The Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock investment value today

Current value as on today

₹2,54,529

Returns

₹1,54,529

(+154.53%)

Returns from Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Stock

₹1,31,472 (+131.47%)

Dollar Impact

₹23,057 (+23.06%)

Analyst Recommendation on Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Indian Investors' Interest in Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Stock

Search interest for Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Stock has increased by 225% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:225% versus previous 30 day period

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
13
14
14
15
13
16
17
16
16
18
Gross Profit
7
8
9
9
8
11
11
10
8
11
Operating Income
-36
-27
-22
-27
-22
-36
-6
-4
-7
-10
EBITDA
-35
-26
-21
-21
-20
-8
12
-3
147
-19
Interest Expense
2
2
6
2
2
2
2
1
3
1
Depreciation
1
1
3
-1
1
1
1
1
1
-
Income Before Tax
-39
-28
-26
-25
-24
-11
8
-6
142
0
Income Tax Expense
-1
-2
0
0
-
-
0
0
5
0
Net Income
-15
-10
-12
-6
-10
15
5
-3
110
0
Net Profit Margin
-118.32%
-73.50%
-87.96%
-44.74%
-80.55%
94.35%
33.18%
-24.49%
688.20%
-2.50%

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
16
187
26
36
45
68
75
84
57
63
Gross Profit
5
26
20
26
31
36
44
61
36
42
Operating Income
-65
-89
-119
-110
-94
-188
-203
-142
-110
-70
EBITDA
-66
-88
-118
-88
-87
-146
-193
-135
-104
-20
Interest Expense
3
7
10
11
15
15
13
12
9
8
Depreciation
-
3
2
4
5
6
9
8
4
4
Income Before Tax
-71
-98
-130
-101
-102
-164
-213
-153
-120
-33
Income Tax Expense
-12
1
0
-49
0
0
0
0
0
0
Net Income
-55
-66
-84
-39
-46
-64
-86
-60
-45
6
Net Profit Margin
-334.31%
-35.65%
-313.02%
-109.09%
-102.03%
-94.06%
-114.30%
-71.75%
-79.75%
10.77%

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-39
-10
-26
-26
-24
-11
8
-5
110
Operating Cash Flow
-25
-21
-20
-12
-19
-27
-6
-12
203
Investing Cash Flow
-
-
-
-15
1
6
2
7
-
Financing Cash Flow
27
14
2
25
52
4
15
5
-27
Change in Cash
2
-7
-17
-2
33
-16
11
-6
176

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-99
-130
-101
-102
-164
-213
-154
-120
-32
Operating Cash Flow
-85
-98
-94
-83
-116
-179
-128
-80
-65
Investing Cash Flow
-41
18
20
-7
40
-22
-2
-15
10
Financing Cash Flow
150
50
146
172
148
75
32
70
77
Change in Cash
27
-29
71
81
72
-127
-97
-24
21

Global Institutional Holdings in Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Funds
Holdings
Shikiar Asset Management Inc
0%

Insights on Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, FBIOP stock has moved up by 64.7%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 16.03M → 18.71M (in $), with an average increase of 14.3% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 491.1% return, outperforming this stock by 352.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 629.2% return, outperforming this stock by 519.8%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 110.37M → -468.0K (in $), with an average decrease of 100.4% per quarter

About Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
OrganisationFortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Headquarters1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
IndustryBiotechnology
CEODr. Lindsay Allan Rosenwald M.D.
E-voting on sharesClick here to vote

Key Management of Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Name

Title

Mr. David Jin

CFO & Head of Corporate Development

Dr. Xiaoqin Lu M.D.

Chief Strategy Officer

Mr. Michael S. Weiss Esq., J.D.

Executive Vice Chairman of Strategic Development & Director

Dr. Lindsay Allan Rosenwald M.D.

Executive Chairman, President & CEO

FAQs

What is Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock share price today?

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock share price today is $18.24 as on at the close of the market. Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock share today touched a day high of $18.33 and a low of $18.05.

What is the 52 week high and 52 week low for Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock share?

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock share touched a 52 week high of $0.00 on and a 52 week low of $0.00 on . Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock price today i.e. is closed at $18.24,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock's market capitalisation today?

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock market capitalisation is $0.00T as on .

How to invest in Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Stock (FBIOP) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Shares that will get you 0.0822 shares as per Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock share price of $18.24 per share as on August 20, 2026 at 1:28 am IST.

What is the minimum amount required to buy Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Stock (FBIOP) from India?

Indian investors can start investing in Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) shares with as little as ₹95.743 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.43 in Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock (as per the Rupee-Dollar exchange rate as on ). Based on Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock share’s latest price of $18.24 as on August 20, 2026 at 1:28 am IST, you will get 0.5482 shares of Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock. Learn more about fractional shares .

What are the returns that Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has given to Indian investors in the last 5 years?

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock has given -26.38% share price returns and 28.54% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?